Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of FRSW107 in Children with Severe Hemophilia A
NCT05251090Phase 1Completed
- Sponsor
- Gensciences
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant human coagulation factor viii-fc fusion protein in hemophilia A, sponsored by Gensciences. Primary endpoints: Maximum measured concentration of FVIII:C, Terminal half-life and 2 more. Started Jun 2021; status: completed.
02
Drugs
recombinant human coagulation factor viii-fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05251090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251090.